| Market Capitalization (Millions $) |
817 |
| Shares
Outstanding (Millions) |
36 |
| Employees |
382 |
| Revenues (TTM) (Millions $) |
199 |
| Net Income (TTM) (Millions $) |
-17 |
| Cash Flow (TTM) (Millions $) |
-27 |
| Capital Exp. (TTM) (Millions $) |
2 |
Harrow Inc
Harrow Health Inc is a publicly-traded, US-based company that specializes in designing, developing and marketing branded prescription and over-the-counter (OTC) pharmaceutical products. The company was founded in 2017 and is headquartered in Nashville, Tennessee. Harrow Health is led by its CEO, Mark L. Baum, who has over 30 years of experience in the pharmaceutical industry.
The company's business model is centered around the development and commercialization of high-quality, affordable and innovative drug products. Harrow Health focuses primarily on niche markets, targeting pharmaceuticals that are used to treat underserved diseases and conditions. The company has an experienced team of medical professionals, researchers and executives who are committed to driving growth through a blend of branded and generic drug products.
Harrow Health's portfolio includes FDA-approved branded drugs and OTC products for the treatment of hypothyroidism, glaucoma, insomnia, and diminished sex drive among others. The company also has a strong pipeline of products under development, including products targeting dry eye disease, neuropathic pain, and acute migraines.
One of Harrow Health's key strengths is its proprietary technologies - the company has developed unique systems for manufacturing and delivering medications that improve efficiency, reduce waste and reduce overall production costs. This allows Harrow Health to offer its products at competitive prices while maintaining high margins and profitability.
Harrow Health operates through its subsidiaries, ImprimisRx and Park Compounding. ImprimisRx is a compounding pharmacy that specializes in preparing customized medications for patients with specific medical needs. Park Compounding, on the other hand, is focused on developing and testing new formulations, with the goal of improving the effectiveness and tolerability of existing drugs.
Harrow Health's growth strategy includes both organic growth and acquisitions. The company is actively pursuing acquisitions of other pharmaceutical companies and assets that align with its business model and strategic objectives. In addition, Harrow Health is focused on expanding its product offerings and leveraging its existing technologies to launch new products for underserved markets.
Overall, Harrow Health is a dynamic and rapidly-growing pharmaceutical company that is committed to bringing innovative and affordable products to market. With a strong leadership team, proprietary technologies and a robust product pipeline, the company is poised for continued success in the years ahead.
Company Address: 1A Burton Hills Blvd. Nashville 37215 TN
Company Phone Number: 733-4730 Stock Exchange / Ticker: NASDAQ HROW
|
2.4% 
99.55 %